{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:25:14Z","timestamp":1791523514545,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41429-022-00537-3","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T08:05:14Z","timestamp":1655453114000},"page":"454-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era"],"prefix":"10.1038","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-7910","authenticated-orcid":false,"given":"Priya","family":"Sreenivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudesh","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Angrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","unstructured":"Santajit S, Indrawattana N, Mechanisms of antimicrobial resistance in ESKAPE Pathogens. Biomed Res Int. 2016;2016. https:\/\/doi.org\/10.1155\/2016\/2475067.","DOI":"10.1155\/2016\/2475067"},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics9100693","volume":"9","author":"G Taggar","year":"2020","unstructured":"Taggar G, Attiq Rheman M, Boerlin P, Diarra MS. Molecular epidemiology of carbapenemases in enterobacteriales from humans, animals, food, and the environment. Antibiotics. 2020;9:1\u201322. https:\/\/doi.org\/10.3390\/antibiotics9100693.","journal-title":"Antibiotics"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.idc.2016.02.005","volume":"30","author":"KS Kaye","year":"2016","unstructured":"Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. Agents of last resort: polymyxin resistance. Infect Dis Clin North Am. 2016;30:391\u2013414. https:\/\/doi.org\/10.1016\/j.idc.2016.02.005.","journal-title":"Infect Dis Clin North Am"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"103887","DOI":"10.1016\/j.micpath.2019.103887","volume":"139","author":"A Pormohammad","year":"2020","unstructured":"Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Micro Pathog. 2020;139:103887. https:\/\/doi.org\/10.1016\/j.micpath.2019.103887.","journal-title":"Micro Pathog"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jinf.2017.09.008","volume":"75","author":"N Prim","year":"2017","unstructured":"Prim N, Turbau M, Rivera A, Rodr\u00edguez-Navarro J, Coll P, Mirelis B. Prevalence of colistin resistance in clinical isolates of Enterobacteriaceae: A four-year cross-sectional study. J Infect. 2017;75:493\u20138. https:\/\/doi.org\/10.1016\/j.jinf.2017.09.008.","journal-title":"J Infect"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/jcm8070934","volume":"8","author":"N Petrosillo","year":"2019","unstructured":"Petrosillo N, Taglietti F, Granata G. Treatment options for colistin resistant klebsiella pneumoniae: present and future. J Clin Med. 2019;8:934. https:\/\/doi.org\/10.3390\/jcm8070934.","journal-title":"J Clin Med"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2147\/IDR.S253631","volume":"13","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li F, Cui S, Mao L, Li X, Awan F, et al. Prevalence and distribution characteristics of blaKPC-2 and blaNDM-1 genes in Klebsiella pneumoniae. Infect Drug Resist. 2020;13:2901\u201310. https:\/\/doi.org\/10.2147\/IDR.S253631.","journal-title":"Infect Drug Resist"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10096-014-2249-x","volume":"34","author":"M Kazi","year":"2015","unstructured":"Kazi M, Drego L, Nikam C, Ajbani K, Soman R, Shetty A, et al. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai. Eur J Clin Microbiol Infect Dis. 2015;34:467\u201372. https:\/\/doi.org\/10.1007\/s10096-014-2249-x.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"537_CR9","doi-asserted-by":"publisher","unstructured":"Deepjyoti P, Atul G, and Amitabha B. Microbial drug resistance. 2017. 815-21. https:\/\/doi.org\/10.1089\/mdr.2016.0124.","DOI":"10.1089\/mdr.2016.0124"},{"key":"537_CR10","first-page":"672","volume":"140","author":"BA Fomda","year":"2014","unstructured":"Fomda BA, Khan A, Zahoor D. Danish NDM-1 (New Delhi metallo beta lactamase-1) producing Gram-negative bacilli. Indian J Med Res. 2014;140:672\u20138.","journal-title":"Indian J Med Res"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/CMR.00001-07","volume":"20","author":"AM Queenan","year":"2007","unstructured":"Queenan AM, Bush K. Carbapenemases: The versatile \u03b2-lactamases. Clin Microbiol Rev. 2007;20:440\u201358. https:\/\/doi.org\/10.1128\/CMR.00001-07.","journal-title":"Clin Microbiol Rev"},{"key":"537_CR12","doi-asserted-by":"publisher","unstructured":"Evans BA and Amyes SGB, \u201cOXA \u03b2-lactamases\u201d, Clin Microbiol Rev., 27, 2, 241\u2013263, 2014. https:\/\/doi.org\/10.1128\/CMR.00117-13.","DOI":"10.1128\/CMR.00117-13"},{"key":"537_CR13","doi-asserted-by":"publisher","unstructured":"Tan X, Kim HS, Baugh K, Huang Y, Kadiyala N, Wences M, et al. Therapeutic options for metallo-\u03b2-lactamase-producing enterobacterales. Infect Drug Resist. 2021;14:125-42. https:\/\/doi.org\/10.2147\/IDR.S246174.","DOI":"10.2147\/IDR.S246174"},{"key":"537_CR14","unstructured":"CLSI, CLSI M100-ED29: 2019 Performance Standards for Antimicrobial Susceptibility Testing, 29th Edition. 2019."},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1128\/AAC.49.7.2959-2964.2005","volume":"49","author":"GA Pankey","year":"2005","unstructured":"Pankey GA, Ashcraft DS. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:2959\u201364. https:\/\/doi.org\/10.1128\/AAC.49.7.2959-2964.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4103\/ijmm.IJMM_17_189","volume":"35","author":"S Laishram","year":"2017","unstructured":"Laishram S, Pragasam AK, Bakthavatchalam YD, Veeraraghavan B. An update on the technical, interpretative, and clinical relevance of antimicrobial synergy testing methodologies. Indian J Med Microbiol. 2017;35:445\u201368. https:\/\/doi.org\/10.4103\/ijmm.IJMM_17_189.","journal-title":"Indian J Med Microbiol"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1128\/AAC.00497-10","volume":"54","author":"MM Sopirala","year":"2010","unstructured":"Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, et al. Synergy testing by etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:4678\u201383. https:\/\/doi.org\/10.1128\/AAC.00497-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.diagmicrobio.2017.05.009","volume":"88","author":"E Wenzler","year":"2017","unstructured":"Wenzler E, Deraedt MF, Harrington AT, Danizger LH. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-\u03b2-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect Dis [Internet]. 2017;88:352\u20134. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.05.009.","journal-title":"Diagn Microbiol Infect Dis [Internet]"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1128\/AAC.00607-13","volume":"57","author":"M McLaughlin","year":"2013","unstructured":"McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57:5131\u20133. https:\/\/doi.org\/10.1128\/AAC.00607-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2666-5247(21)00039-2","volume":"2","author":"E Afshinnekoo","year":"2021","unstructured":"Afshinnekoo E, Bhattacharya C, Burguete-Garc\u00eda A, Castro-Nallar E, Deng Y, Desnues C, et al. COVID-19 drug practices risk antimicrobial resistance evolution. Lancet Microbe. 2021;2:e135\u2013e136. https:\/\/doi.org\/10.1016\/S2666-5247(21)00039-2.","journal-title":"Lancet Microbe"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijid.2020.12.087","volume":"104","author":"MAB Lucien","year":"2021","unstructured":"Lucien MAB, Canarie MF, Kilgore PE, Jean-Denis G, F\u00e9n\u00e9lon N, Pierre M, et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. Int J Infect Dis. 2021;104:250\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2020.12.087.","journal-title":"Int J Infect Dis"},{"key":"537_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","volume":"8","author":"D van Duin","year":"2017","unstructured":"van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017;8:460\u20139. https:\/\/doi.org\/10.1080\/21505594.2016.1222343.","journal-title":"Virulence"},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-920","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-920.","journal-title":"Lancet Infect Dis"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3.","journal-title":"Lancet Infect Dis"},{"key":"537_CR26","doi-asserted-by":"publisher","unstructured":"Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, et al. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61. https:\/\/doi.org\/10.1128\/aac.00642-17.","DOI":"10.1128\/aac.00642-17"},{"key":"537_CR27","doi-asserted-by":"publisher","unstructured":"Lomovskaya O, \u201cVaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae,\u201d Antimicrob. Agents Chemother., 61, 2017. https:\/\/doi.org\/10.1128\/AAC.01443-17.","DOI":"10.1128\/AAC.01443-17"},{"key":"537_CR28","doi-asserted-by":"publisher","first-page":"e02243","DOI":"10.1128\/AAC.02243-16","volume":"61","author":"S Marshall","year":"2017","unstructured":"Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, et al. Can ceftazidime-avibactamand aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61:e02243\u201316. https:\/\/doi.org\/10.1128\/AAC.02243-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR29","doi-asserted-by":"publisher","unstructured":"Karlowsky JA, Kazmierczak KM, De Jonge BLM, Hackel MA, Sahm DF, Bradford PA. In vitro activity of aztreonam-avibactam against enterobacteriaceae and pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother., 2017;61:e00472\u201317. https:\/\/doi.org\/10.1128\/AAC.00472-17.","DOI":"10.1128\/AAC.00472-17"},{"key":"537_CR30","doi-asserted-by":"publisher","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","volume":"61","author":"B Davido","year":"2017","unstructured":"Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:e01008\u201317. https:\/\/doi.org\/10.1128\/AAC.01008-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR31","doi-asserted-by":"publisher","unstructured":"Benchetrit L, Mathy V, Armand-Lefevre L, Bouadma L, Timsit J-F. Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases. Int J Antimicrob Agents. 2020;55. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.023.","DOI":"10.1016\/j.ijantimicag.2019.10.023"},{"key":"537_CR32","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.2147\/IDR.S273989","volume":"13","author":"C Zou","year":"2020","unstructured":"Zou C, Wei J, Shan B, Chen X, Wang D, Niu S. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant enterobacteriaceae isolates collected from three secondary hospitals in southwest China between 2018 and 2019. Infect Drug Resist. 2020;13:3563\u20138. https:\/\/doi.org\/10.2147\/IDR.S273989.","journal-title":"Infect Drug Resist"},{"key":"537_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijid.2020.05.075","volume":"97","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhu Z, Jia W, Qu F, Huang B, Shan B, et al. In vitro activity of aztreonam\u2013avibactam against metallo-\u03b2-lactamase-producing Enterobacteriaceae\u2014A multicenter study in China. Int J Infect Dis. 2020;97:11\u201318. https:\/\/doi.org\/10.1016\/j.ijid.2020.05.075.","journal-title":"Int J Infect Dis"},{"key":"537_CR34","doi-asserted-by":"publisher","first-page":"e01944","DOI":"10.1128\/JCM.01944-19","volume":"58","author":"E Ransom","year":"2020","unstructured":"Ransom E, Bhatnagar A, Patel JB, Machado MJ, Boyd S, Reese N et al. Validation of Aztreonam-Avibactam susceptibility testing using digitally dispensed custom panels. J Clin Microbiol. 2020;58:e01944\u201319. https:\/\/doi.org\/10.1128\/JCM.01944-19.","journal-title":"J Clin Microbiol"},{"key":"537_CR35","doi-asserted-by":"publisher","first-page":"515.e1","DOI":"10.1016\/j.cmi.2018.11.025","volume":"25","author":"A Chauzy","year":"2019","unstructured":"Chauzy A, Buyck J, de Jonge BLM, Marchand S, Gr\u00e9goire N, Couet W. Pharmacodynamic modeling of \u03b2-lactam\/\u03b2-lactamase inhibitor checkerboard data: illustration with aztreonam\u2013avibactam. Clin Microbiol Infect. 2019;25:515.e1\u2013515.e4. https:\/\/doi.org\/10.1016\/j.cmi.2018.11.025.","journal-title":"Clin Microbiol Infect"},{"key":"537_CR36","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, Cisneros JM, Torre-Cisneros J, Rodr\u00edguez-Hern\u00e1ndez MJ, Tall\u00f3n-Aguilar L, Calbo E. COMBACTE-CARE consortium\/REJUVENATE Study G.Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020;75:618\u201327. https:\/\/doi.org\/10.1093\/jac\/dkz497.","journal-title":"J Antimicrob Chemother"},{"key":"537_CR37","doi-asserted-by":"publisher","unstructured":"Sadek M, Juhas M, Poirel L, Nordmann P, Genetic Features leading to reduced susceptibility to Aztreonam-Avibactam among Metallo-\u03b2-Lactamase-Producing Escherichia coli Isolates. Antimicrob Agents Chemother. 2020;64. https:\/\/doi.org\/10.1128\/AAC.01659-20.","DOI":"10.1128\/AAC.01659-20"},{"key":"537_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/jac\/dkz468","volume":"75","author":"S Niu","year":"2020","unstructured":"Niu S, Wei J, Zou C, Chavda KD, Lv J, Zhang H, et al. In vitro selection of aztreonam\/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2020;75:559\u201365. https:\/\/doi.org\/10.1093\/jac\/dkz468.","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00537-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T12:08:08Z","timestamp":1744027688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00537-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1038\/s41429-022-00537-3","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has been approved by the Institution Ethics Committee, PGIMER, Chandigarh vide no INT\/IEC\/2021\/SPL-863, Dated \u2013 25\/05\/2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical clearance"}},{"value":"This study has been conducted from patient\u2019s samples which are collected for routine diagnostic purposes. No separate sample was collected for the study purpose. Hence patient consent was not taken for conducting this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient\u2019s consent"}}]}}